FDA Moving to Bring Back Popular Injectable Peptides
The FDA is moving to allow compounding pharmacies to produce over a dozen banned injectable peptides. RFK Jr. says he's a big fan and has used them with great results.
/ 40 items
#HIMS↓
Novo & Hims Partner on Ozempic & Wegovy – Lawsuit Dropped
Novo Nordisk and Hims & Hers end their legal battle and team up to offer FDA-approved Ozempic and Wegovy (injections and pills) on the Hims platform. Hims shifts its focus to branded GLP-1s with limited compounded options. Shares surge.
From Lawsuit to Love: Novo Nordisk Teams Up with Hims & Hers Again
Novo Nordisk is set to sell its popular weight-loss drugs like Wegovy on Hims & Hers platform soon, surprising many after a recent lawsuit over copycat versions. This could boost access and help both companies in the competitive obesity market.
FDA Cracks Down Hard — 30 Telehealth Companies Warned Over Compounded Ozempic & Zepbound Copies
The FDA sent warning letters to 30 telehealth companies for false claims about compounded GLP-1 drugs like semaglutide and tirzepatide.
Hims & Hers Surges as RFK Jr. Pushes Easier Peptide Access
Hims & Hers jumps over 13% after HHS Secretary RFK Jr. told Joe Rogan he's pushing to make key peptides more accessible via compounding, potentially boosting the telehealth company's growth in wellness treatments.
Hims & Hers Beats Profit Expectations, Guides Above Estimates After Weight-Loss Blowup
Hims & Hers (HIMS) beat profit expectations in Q4 2025 with $2.35B full-year revenue (up 59%). 2026 forecast of $2.7-2.9B tops analyst views as the company expands globally after its cheap Wegovy copy plan backfired.